MBFUSEDIT

Molecular Basis for Unwanted Side-Effects During Interferon Therapy

Coordinatore	UNIVERSITAETSKLINIKUM FREIBURG    more  Organization address address: HUGSTETTER STRASSE 49 city: FREIBURG postcode: 79106 contact info Titolo: Mr. Nome: Juergen Cognome: Dreyer Email: send email Telefono: 496713000000 Fax: 497613000000
Nazionalità Coordinatore	Germany [DE]
Totale costo	75˙000 €
EC contributo	75˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2009-RG
Funding Scheme	MC-IRG
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-09-01   -   2014-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITAETSKLINIKUM FREIBURG  Organization address address: HUGSTETTER STRASSE 49 city: FREIBURG postcode: 79106 contact info Titolo: Mr. Nome: Juergen Cognome: Dreyer Email: send email Telefono: 496713000000 Fax: 497613000000	DE (FREIBURG)	coordinator	75˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'First-line immunomodulatory treatments such as beta-interferons (IFN-alpha/beta) for multiple sclerosis are available to reduce the rate of relapses and disease activity. However, in addition to its therapeutic effect, systemic IFN-beta treatment causes severe neuropsychiatric complications in humans, including depression and cognitive impairments. These side effects are common and can limit the treatment utility. Our long-term goal is to elucidate the molecular mechanisms of these unwanted side effects in order to improve IFN-beta therapy. The specific hypothesis is that systemically applied IFN-beta exerts adverse side effects by activation of the respective receptor of type I interferons (IFNAR) in the central nervous system (CNS). To identify the actual cell type targeted by IFN-beta in the brain, we have generated brain-specific and glia-specific IFNAR-deficient mice. With the help of these animals we will determine which interferon-stimulated genes will be activated in the brain upon systemic IFN-beta application. We will further assess the contribution of central IFNARs to IFN-beta mediated “sickness” behavior, which includes depressive-like behavior and cognitive impairment and we will correlate these behaviors to changes in hippocampal synaptic plasticity. Together, these experiments will be crucial to identify neurobiological mechanisms responsible for the unfavorable side effects accompanying IFN-beta therapy and to evaluate interventions to ameliorate them.'

Introduzione (Teaser)

Understanding how type I interferons function is central to predicting unwanted responses during therapy.